Litcius/Paper detail

SARS-CoV-2 RNA in the Cerebrospinal Fluid of a Patient with Long COVID

Daša Viszlayová, Martin Sojka, Silvia Dobrodenková, Szabolcs Szabó, Ondrej Bilec, Mária Turzová, Juraj Ďurina, Barbara Baloghová, Zoltán Borbély, Martin Kršák

2021Therapeutic Advances in Infectious Disease40 citationsDOIOpen Access PDF

Abstract

Over 10% of COVID-19 convalescents report post-COVID-19 complications, namely, 'long COVID' or 'post-COVID syndrome,' including a number of neuro-psychiatric symptoms. The pathophysiology of COVID-19 in the central nervous system is poorly understood but may represent post-COVID injury, ongoing sterile maladaptive inflammation, or SARS-CoV-2 persistence. We describe a long COVID patient with SARS-CoV-2 RNA in the cerebrospinal fluid, which seems important, specifically due to recent reports of gray matter volume loss in COVID-19 patients. Further studies of SARS-CoV2 RNA, markers of inflammation, and neuronal damage in the CSF of patients with long COVID would be useful and should address whether the CNS can serve as a reservoir of SARS-CoV-2, clarify the pathway by which COVID-19 contributes to CNS dysfunction, and how best to therapeutically address it.

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Cerebrospinal fluidSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Medicine2019-20 coronavirus outbreakPathophysiologyInflammationCoronavirusCentral nervous systemVirologyPathologyImmunologyInternal medicineDiseaseOutbreakInfectious disease (medical specialty)Long-Term Effects of COVID-19Neuroinflammation and Neurodegeneration MechanismsVestibular and auditory disorders